Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C133238
http://purl.obolibrary.org/obo/NCIT_C133238
|
|---|---|
| Preferred Name | Niraparib Tosylate Monohydrate |
| Definitions |
An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks. |
|---|---|
| prefLabel | Niraparib Tosylate Monohydrate
|
| label | Niraparib Tosylate Monohydrate
|
| NCI_META_CUI | CL520459
|
| PDQ_Closed_Trial_Search_ID | 615263
|
| code | C133238
|
| Has_Target | |
| prefixIRI | NCIT:C133238
|
| in_subset | |
| Preferred_Name | Niraparib Tosylate Monohydrate
|
| FDA_UNII_Code | 195Q483UZD
|
| Contributing_Source | FDA
|
| Maps_To | Niraparib Tosylate Monohydrate
|
| CAS_Registry | 1613220-15-7
|
| NCI_Drug_Dictionary_ID | 615263
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 615263
|
| Accepted_Therapeutic_Use_For | maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |